AGREEMENT OF SUBLEASE between ABN AMRO HOLDING USA LLC as Sublandlord and ACTINIUM PHARMACEUTICALS, INC. as Subtenant Premises: Entire 23rd Floor New York, New York 10017 AGREEMENT OF SUBLEASESublease Agreement • August 12th, 2022 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS AGREEMENT OF SUBLEASE (this “Sublease”), made and entered into as of the __ day of April, 2022, by and between ABN AMRO HOLDING USA LLC, a Delaware limited liability company, having offices at 100 Park Avenue, New York, New York 10017 (“Sublandlord”), and ACTINIUM PHARMACEUTICALS, INC., a Delaware corporation, having offices at 275 Madison Avenue, New York, New York 10016 (“Subtenant”).
EXCLUSIVE LICENSE AND SUPPLY AGREEMENTExclusive License and Supply Agreement • August 12th, 2022 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • England and Wales
THIS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT (“Agreement”) is made effective as of the 7th day of April, 2022 (the “Effective Date”), by and between Immedica Pharma AB, a corporation organized and existing under the laws of Sweden with registration number, 556835-6322 and offices at Norrtullsgatan 15, SE 113 29 Stockholm, Sweden (“IMMEDICA”) and Actinium Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware and with offices at 275 Madison Avenue, 7th Floor, New York, NY 10016, U.S.A. (“LICENSOR”). IMMEDICA and LICENSOR may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
